In general, the term "oxidative stress" describes an imbalance between oxidants and antioxidants in favor of the oxidants. While antioxidant defense is widely accepted to involve both enzymatic and non-enzymatic reactions, oxidants are generally assumed to be produced by non-enzymatic processes involving chemically produced free radicals. However, many oxidants are also formed by numerous enzymes and proteins. The F 2 -isoprostane 8-iso-prostaglandin F 2α (8-iso-PGF 2α ) and malondialdehyde (MDA) are widely used as biomarkers of oxidative stress, although there is evidence that both 8-iso-PGF 2α and MDA are also produced enzymatically from arachidonic acid by the action of cyclooxygenase (COX). On the contrary, there is also evidence that PGF 2α is produced from arachidonic acid both by the action of COX and non-enzymatically. The duality of oxidative stress, personified by 8-iso-PGF 2α and PGF 2α , is a serious dilemma and demands new definitions and strategies from the scientists.
Introduction
There is solid evidence that 8-iso-prostaglandin F 2α (PGF 2α ) is produced both enzymatically and non-enzymatically in vivo in animals and in humans. This evidence is based on the inhibitory action of cyclooxygenase (COX) inhibitors and has been reported by many groups (1) (2) (3) . For many decades, PGF 2α has been thought to be exclusively formed from arachidonic acid by the catalytic action of COX. Yet, there is also solid evidence that PGF 2α is an abundant non-enzymatic oxidation product of arachidonic acid (4) . van't Erve et al. (5) proposed that the 8-iso-PGF 2α /PGF 2α molar ratio can be used to distinguish chemical from enzymatic lipid peroxidation. Yet, the key information that the isomeric prostaglandins 8-iso-PGF 2α and PGF 2α can be produced from arachidonic acid via enzymatic and nonenzymatic processes has not been considered by van't Erve and colleagues (5) . It is worth mentioning that these authors have demonstrated that recombinant prostaglandin H synthase (PGHS) isoforms 1 (PGHS-1) and 2 (PGHS-2), also known as COX-1 and COX-2, respectively, catalyze the formation of 8-iso-PGF 2α from free arachidonic acid (5) . This finding confirms our recent finding on recombinant PGHS-1 and PGHS-2 (3). We also showed that PGHS-1 and PGHS-2 catalyze the synthesis of malondialdehyde (MDA) and 12-hydroxy-heptadecatrienoic acid (12-HHT), with MDA being a generally accepted biomarker of oxidative stress.
Paradoxically, we found in the same study that reduced glutathione (GSH), the most abundant intracellular lowmolecular-mass antioxidant, promotes the formation of 8-iso-PGF 2α , MDA, and 12-HHT (3).
Can we distinguish enzymatic from non-enzymatic sources of PGF 2α , 8-iso-PGF 2α , MDA, and 12-HHT?
Generally, the proportion of enzymatic and non-enzymatic pathways contributing to PGF 2α , 8-iso-PGF 2α , MDA, and 12-HHT is unknown and is likely to vary greatly in biological systems. Alternative approaches to distinguish enzymatic and non-enzymatic pathways have been proposed. They involve the use of the molar ratio of 8-iso-PGF 2α to another prostanoid such as the parent molecule arachidonic acid (6) or prostaglandin E 2 (PGE 2 ) (3, 7) ( Figure. 1 ). PGE 2 is arbitrarily assumed to being exclusively produced from arachidonic acid by PGHS. Yet, the exclusive source of PGHS for PGE 2 remains to be demonstrated. Noteworthy, 8-iso-PGE 2 is known to readily and spontaneously isomerize to PGE 2 , so that the origin of PGE 2 and its metabolites measured in biological samples are eventually uncertain. This may also apply to prostacyclin (PGI 2 ) and thromboxane A 2 (TxA 2 ) (8). These issues underline the Gordian nature of oxidative stress. In general, measurement of primary prostanoids in blood (plasma and serum) is not recommended because of their abundant ex vivo formation (discussed in Ref. [9] of this article). In healthy humans, plasma PGF 2α concentration ranges between 2 and 11 pg/mL (9) . The concentration of free, nonesterified 8-iso-PGF 2α in plasma of healthy non-smoking volunteers is of the order of 3-10 pg/mL as measured by two highly specific methods, that is, by the combination of immunoaffinity chromatography (IAC) column extraction of 8-iso-PGF 2α with GC-MS/MS (9). van't Erve et al. reported 5-10 times higher plasma concentrations (range, 50 and 110 pg/mL) for 8-iso-PGF 2α and PGF 2α in healthy humans (5) . This discrepancy challenges the specificity of the LC-MS/MS methodology as well as the reliability of measuring plasma concentrations of 8-iso-PGF 2α , PGF 2α , and other primary prostanoids which circulate in blood at concentrations generally below 10 pg/mL (8, 9) . The low concentration range is a big analytical challenge for every analytical methodology presently available including GC-MS/MS, but much more so for LC-MS/MS (9) . As a consequence of this, the use of molar ratios such as 8-iso-PGF 2α to PGF 2α in plasma is likely to lead to disputable results. Similar difficulties may also apply to other biological samples including urine because of different origin and metabolism of 8-iso-PGF 2α and PGF 2α excreted in the urine. In addition, PGHS inhibitors may exert distinctly different effects on 8-iso-PGF 2α in humans and in widely used experimental animals such as rats (8) . Implementation of IAC techniques for the specific separation and isolation of 8-iso-PGF 2α and PGF 2α from the remaining potentially interfering 62 F 2 -prostaglandins prior to LC-MS/MS or GC-MS/MS analysis is recommended.
Analytical and methodological issues contributing to uncertainty and controversies
The input of data obtained under very different conditions into a formula such as that proposed by van't Erve et al. (5) for distinguishing between chemical and enzymatic generation of 8-iso-PGF 2α and PGF 2α , as well as for quantifying the relative contribution of the enzymatic and non-enzymatic pathways, is problematic for the following reasons: (a) Data on 8-iso-PGF 2α obtained from rats and humans are hard to compare (see Ref. Figure 1 panels (C) and (D) of a previous study (7) . enzymatic peroxidation of arachidonic acid. Finally, (e) the measurement of 8-iso-PGF 2α and PGF 2α in blood is not suitable for the reasons discussed above. With respect to the very long incubation time of at least 5 h, it should be emphasized that "oxidative stress" occurs immediately upon addition of arachidonic acid to PGHS (3) under experimental condi-tions very similar to those used by van't Erve et al. (5) . For instance, in the presence of recombinant PGHS-1 or PGHS-2 and arachidonic acid (10 µM), the thiols glutathione (100 µM) or L-cysteine (100 µM) are rapidly oxidized to their disulfides in a stoichiometry of about 1:1 with respect to arachidonic acid, and the reaction is already completed after about 20-30 min of incubation at 37°C (3). PGE 2 is the major reaction product that is generated from arachidonic acid by recombinant PGHS-1 and PGHS-2 (3). In the absence of thiols, synthetic PGG 2 decomposes spontaneously to a minor extent to PGE 2 in a manner independent of hematin and phenol ( Figure 2A) ; the latter are recommended and commonly used in activity assays of isolated and recombinant PGHS-1 and PGHS-2. Under the same conditions, synthetic PGH 2 decomposes mainly to PGE 2 to a much higher extent of 70%-80% (Figure 2A ). In the presence Figure 2 . Formation of PGE 2 and PGF 2α from synthetic PGG 2 and PGH 2 in buffer at 37°C after incubation for 10 min. (a) Each 1000 nM of PGG 2 and PGH 2 were incubated in complete buffer (2 mM phenol, 1 µM hematin), as well as in the absence of phenol, of hematin or of both. (b) Effect of various concentrations of N-acetyl-L-cysteine (0-50 µM) on the formation of PGE 2 from synthetic PGH 2 used at a nominal concentration of 1000 nM in complete buffer. (c) Effect of reduced glutathione (GSH) used at various concentrations (0-1000 µM) on the formation of PGE 2 from synthetic PGG 2 and PGH 2 used at a nominal concentration of 10,000 nM each in complete buffer. Experimental conditions and prostanoids analysis were as described elsewhere (3) . Data are shown as mean and standard deviation of two independent experiments.
The dilemma of oxidative stress of the thiol N-acetyl-L-cysteine ( Figure 2B ) or glutathione ( Figure 2C ), the decomposition of PGH 2 to PGE 2 decreases, while the formation of F 2 -prostanoids such as 8-iso-PGF 2α , 9β,11α-PGF 2α , 15-keto-PGF 2α , and PGF 2α increases several fold. On the contrary, thiols seem not to affect decomposition of synthetic PGG 2. Similar effects are also seen in the presence of recombinant PGHS-1 or PGHS-2, yet in the absence of synthetic PGG 2 or PGH 2 , in a manner depending on the incubation time (Figures 3 and 4) . These observations indicate that certain changes in experimental conditions may affect significantly the pattern of prostanoids and consequently of their molar ratios (Figure 4) . Diverging results are also obtained using PGHS inhibitors with different modes of action such as acetylsalicylic acid (irreversible inhibitor) or diclofenac and indomethacin (both reversible inhibitors) (3).
Conclusion
The scientific research area of oxidative stress is highly challenging, and the role attributed to free radicals in the development of chronic diseases and aging process is overestimated (10) . Many of the biomarkers being presently used to quantify oxidative stress, including 8-iso-PGF 2α and MDA, can be generated both by enzymes and free radicals or by nonradical reactive oxygen/nitrogen species, which, in turn, are produced both by enzymes and chemicals especially including transition metal ions. Endogenous substances such as GSH can modulate the fate of intermediates (i.e., PGG 2 and PGH 2 ) in favor of 8-iso-PGF 2α and PGF 2α and at the cost of other prostaglandins such as PGE 2 and PGD 2α , the kinetics and yield of reaction products. Distinguishing "enzymatic" from "non-enzymatic" pathways/reactions that lead to 8-iso-PGF 2α , PGF 2α , and MDA by means of a combination of in vitro and in vivo studies is extremely difficult, if not impossible. The focus in this area should be on those F 2 -prostaglandins which, in theory, are unlikely to be produced from arachidonic acid by the catalytic action of PGHS and/or of other enzymes/proteins. Some of those F 2 -isoprostanes have been sporadically investigated and used as biomarkers of oxidative stress in the past. Studies comparing 8-iso-PGF 2α , a type III (15 series) F 2 -isoprostane, with F 2 -isoprostanes of type IV (8 series), type V (12 series), or VI (5 series) will provide valuable information about the nature of oxidative stress, notably of lipid peroxidation. COX inhibitors and antioxidants, most notably thiols such as N-acetylcysteine, are likely to generate different results in vitro using recombinant PGHS enzymes, in cells, and in vivo in animals and in humans for many different reasons which have not been fully recognized thus far.
8-iso-PGF 2α has been recently declared as "the best biomarker of oxidative stress" in humans, and the 8-iso-PGF 2α / PGF 2α molar ratio has been proposed as a quantitative measure of lipid peroxidation (5) . Yet, scientifically sound evidence has not been provided. The dual nature of oxidative stress and the diprosopus 8-iso-PGF 2α , PGF 2α , and MDA are likely to be objectives of research of scientist generations to come.
